Goodwin Procter advised Subject Matter, and Seyfarth Shaw advised Kivvit. Subject Matter, a portfolio company of Coral Tree Partners, announced its acquisition of Kivvit to create...
You must be a Standard 1 Year member to access this content.
Goodwin Procter acted as counsel to FibroGen, and Gibson Dunn acted as counsel to Morgan Stanley Tactical Value. FibroGen, Inc. (NASDAQ: FGEN) announced a non-dilutive term...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised GeneWerk on the deal. GeneWerk announced its merger with Protagen Protein Services. GeneWerk, an Ampersand portfolio company, is a cell and gene therapy testing...
You must be a Standard 1 Year member to access this content.
Paul Hastings advised 2U, Inc. on the deal while Goodwin Procter represented edX. 2U, Inc., a global leader in education technology, announced a definitive agreement to acquire...
You must be a Standard 1 Year member to access this content.
